

## Supporting Information

### **Improved synthesis and application of an alkyne-functionalized isoprenoid analogue to study the prenylomes of motor neurons, astrocytes and their stem cell progenitors**

Kiall F. Suazo,<sup>1</sup> Mishra, Vartika,<sup>2,3</sup> Sanjay Maity,<sup>1</sup> Shelby A. Auger,<sup>1</sup> Katarzyna Justyna,<sup>1</sup> Alex Petre,<sup>1</sup> Linda Ottoboni,<sup>4</sup> Jessica Ongaro,<sup>6</sup> Stefania P. Corti,<sup>4,6,7</sup> Francesco Lotti,<sup>2,3</sup> Serge Przedborski,<sup>2,3,5</sup> and Mark D. Distefano<sup>1</sup>

<sup>1</sup>Department of Chemistry, University of Minnesota, Minneapolis, MN USA 55455

<sup>2</sup>Center for Motor Neuron Biology and Diseases, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032.

<sup>3</sup>Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032.

<sup>4</sup>Department of Pathophysiology and Transplantation, Dino Ferrari Center, Università degli Studi di Milano, Milan, Italy.

<sup>5</sup>Department of Neuroscience, Pathology, and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032

<sup>6</sup>Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>7</sup>Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

## Table of Contents

### Figures


<b>Figure S1.</b> Products from the oxidation of compound <b>2</b> . .....	4
<b>Figure S2.</b> <sup>1</sup> H-NMR analysis of <b>3b</b> . .....	4
<b>Figure S3.</b> <sup>13</sup> C-NMR analysis of <b>3b</b> . .....	5
<b>Figure S4.</b> COSY NMR analysis of <b>3b</b> . .....	5
<b>Figure S5.</b> HSQC-NMR analysis of <b>3b</b> . .....	6
<b>Figure S6.</b> HMBC-NMR analysis of <b>3b</b> . .....	7
<b>Figure S7.</b> Selective Gradient NOESY analysis of <b>3b</b> . .....	8
<b>Figure S8.</b> LC-MS analysis of the oxidation reaction of compound <b>2</b> . .....	9
<b>Figure S9.</b> Correlation between normalized transcript counts and the fold-change of prenylated proteins ES-MNs. ....	10

### Tables


<b>Table S1:</b> Summary of yields and conditions for the alkylation of <b>3</b> to yield <b>5</b> . .....	11
<b>Table S2:</b> Summary of yields and conditions for the deprotection of <b>5</b> to yield <b>6</b> . .....	11
<b>Table S3.</b> Summary of NMR data for compound <b>3b</b> . .....	12
<b>Table S4:</b> Summary of yields and conditions for the oxidation of <b>2</b> to yield <b>3</b> . .....	13
<b>Table S5:</b> Summary of yields and conditions for the bromination and subsequent diphosphorylation of <b>6</b> to yield <b>1</b> . ....	13
<b>Table S6:</b> Lists of prenylated proteins enriched from ESCs, ES-MNs and ES-As. ....	See separate Excel file
<b>Table S7:</b> Results from gprofiler enrichment analysis of prenylated proteins ESCs, ES-As, and ES-MNs. ....	See separate Excel file
<b>References.</b> .....	14

## Spectral Data for Synthetic Compounds

Compound <b>2</b> $^1\text{H}$ NMR.....	15
Compound <b>3</b> $^1\text{H}$ NMR.....	16
Compound <b>5</b> $^1\text{H}$ NMR .....	17
Compound <b>6</b> $^1\text{H}$ NMR.....	18
Compound <b>1</b> $^1\text{H}$ NMR.....	19
Compound <b>1</b> $^{31}\text{P}$ NMR.....	20
Compound <b>1</b> $^{13}\text{C}$ NMR.....	21



**Figure S1.** Products from the oxidation of compound **2**. The desired oxidation product **3a** containing a hydroxyl group at C-12 along with a second hydroxylated species at C-8 (**3b**). Carbonyl-containing products resulting from over-oxidation at C-12 (**4a**) and C-8 (**4b**) were also observed. The numbering scheme for Farnesol, used for all these products, is shown at the top.



**Figure S2.**  $^1\text{H-NMR}$  analysis of **3b**.




Figure S3.  $^{13}\text{C}$ -NMR analysis of **3b**.







Figure S4. COSY NMR analysis of **3b**.



**Figure S5.** HSQC-NMR analysis of **3b**.




**Figure S6.** HMBC-NMR analysis of **3b**.




**Figure S7.** Selective Gradient NOESY analysis of **3b**.





**Figure S8.** LC-MS analysis of the oxidation reaction of compound **2**. (A) LC-MS analysis of the oxidation reaction of compound **2** after 1 h (i), 22 h (ii) and after NaBH<sub>4</sub> reduction (iii). In the chromatograms, the peaks occurring at 29.7, 30.2, 31.2 and 33.6 are labeled as **3a**, **3b**, **4a** and/or **4b** and **2**, respectively. Those assignments were made on the basis of MS analysis and/or injection of the purified compounds. (B) MS analysis of the peak eluting at 29.7 min showing an m/z value of 345.22 compared to the calculated value of 345.24 for the [M+Na]<sup>+</sup> ion C<sub>20</sub>H<sub>34</sub>O<sub>3</sub>Na. (C) MS analysis of the peak eluting at 30.2 min showing an m/z value of 345.22 compared to the calculated value of 345.24 for the [M+Na]<sup>+</sup> ion C<sub>20</sub>H<sub>34</sub>O<sub>3</sub>Na. (D) MS analysis of the peak eluting at 31.2 min showing an m/z value of 343.19 compared to the calculated value of 343.23 for the [M+Na]<sup>+</sup> ion C<sub>20</sub>H<sub>32</sub>O<sub>3</sub>Na. (E) MS analysis of the peak eluting at 33.6 min showing an m/z value of 329.22 compared to the calculated value of 229.25 for the [M+Na]<sup>+</sup> ion C<sub>20</sub>H<sub>34</sub>O<sub>2</sub>Na. For each mass spectrum, the spacings between the parent peak and M+1 and M+2 isotopologues are highlighted with vertical dashed lines to illustrate that the observed species are singly charged in all cases.



**Figure S9.** Correlation between normalized transcript counts and the fold-change of prenylated proteins ES-MNs. The Log<sub>2</sub> Fold change values of ungrouped prenylated proteins that were found in the ES derived motor neurons display a significant positive correlation ( $p < 0.05$ ) to the Log<sub>2</sub> of normalized transcript counts as determined by Spearman's rank-order correlation with a one tail distribution. Transcript counts (Ikiz et al, 2015) were normalized by gene length then to smallest value.

**Table S1:** Summary of yields and conditions for the alkylation of **3** to yield **5**.

Batch No.	Scale	Purification Conditions	Yield (Temp)
1	1.38 g, 4.30 mmol	EtOAc:Hexane (0:100 to 5:95)	1.01 g, 65% (110 °C)
2	0.66 g, 2.05 mmol	Column length: 2.1 x 15 cm	0.53 g, 72% (85-90 °C)
3	0.43 g, 1.32 mmol	Silica gel	0.33 g, 70% (85-90 °C)
4	0.62 g, 1.92 mmol		0.49 g, 70% (85-90 °C)
5	0.55 g, 1.71 mmol		0.46 g, 75% (85-90 °C)

**Table S2:** Summary of yields and conditions for the deprotection of **5** to yield **6**.

Batch No.	Scale	Purification Conditions	Yield (Temp)
1	1.02g, 2.83 mmol	EtOAc:Hexane (20:80)	0.43 g, 55% (50 °C)
2	1.0 g, 2.8 mmol	Column length: 2.1 x 10 cm	0.64 g, 82% (55-60 °C)
3	0.34 g, 0.94 mmol	Silica gel	0.22 g, 85% (60-65 °C)
4	0.49 g, 1.36 mmol		0.33 g, 89% (60-65 °C)
5	0.49 g, 1.36 mmol		0.37 g, 95% (60-65 °C)

**Table S3.** Summary of NMR data obtained by  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^1\text{H}$ - $^1\text{H}$  COSY,  $^1\text{H}$ - $^{13}\text{C}$  HMBC and 1D Selective Gradient NOESY for compound **3b**.<sup>a</sup>

Position	$\delta_{\text{C}}^b$ type	$\delta_{\text{H}}^c$ ( $J$ in Hz <sup>e</sup> )	HMBC	COSY	1D Selective Gradient NOESY
1	63.74, 63.80, CH <sub>2</sub> <sup>d</sup>	4.26-4.19, m 4.03-3.93, m ( <sup>2</sup> $J_{\text{H,H}} = 14.5$ , <sup>3</sup> $J_{\text{H,H}} = 5.75$ )	2, 3	2	
2	121.00, CH	5.39-5.31, m ( <sup>3</sup> $J_{\text{H,H}} = 5.75$ )	1, 3, 4	1	
3	139.92, 139.93, C <sup>d</sup>		1, 4, 13		
4	39.31, CH <sub>2</sub>	2.08-2.03, m	2, 3, 5, 6, 13	6	
5	25.87, 25.91, CH <sub>2</sub> <sup>d</sup>	2.21-2.11, m	4, 6	6	
6	125.79, CH	5.39-5.31, m ( <sup>3</sup> $J_{\text{H,H}} = 8.3$ , <sup>4</sup> $J_{\text{H,H}} = 7.75$ )	4, 5, 8, 14	4, 5, 14	
7	137.21, C		5, 9, 14		
8	77.30, 77.32, CH <sup>d</sup>	4.03-3.93, m	6, 9, 14	9	
9	34.25, 34.27, CH <sub>2</sub> <sup>d</sup>	2.31-2.22, m	7, 8, 10, 11	8, 10	
10	120.36, CH	5.07, t ( <sup>4</sup> $J_{\text{H,H}} = 6.5$ )	8, 9, 12, 15	9, 12, 15	12
11	134.58, C		9, 10, 12, 15		
12	25.99, CH <sub>3</sub>	1.70, s	10, 11, 12, 15	10	
13	16.47, 16.51, CH <sub>3</sub> <sup>d</sup>	1.66, s	2, 3, 4	2	
14	11.74, 11.77, CH <sub>3</sub> <sup>d</sup>	1.60, s	6, 7, 8	6	
15	18.09, CH <sub>3</sub>	1.62, s	10, 11, 12, 15	10	
1'	97.88, 97.99, CH <sup>d</sup>	4.61, dt ( <sup>3</sup> $J_{\text{H,H}} = 5.0$ , <sup>4</sup> $J_{\text{H,H}} = 2.8$ )	1, 2', 5'	5', 3'	
2'	62.33, 62.35, CH <sub>2</sub> <sup>d</sup>	3.49, dt ( <sup>3</sup> $J_{\text{H,H}} = 10.7$ , <sup>4</sup> $J_{\text{H,H}} = 5.2$ )	1' 3'	3', 4' 5'	
3'	30.77, 30.79, CH <sub>2</sub> <sup>d</sup>	1.45-1.64, m	4'	1', 2', 4'	
4'	19.67, 19.68, CH <sub>2</sub> <sup>d</sup>	1.45-1.64, m	2', 5'	3', 5'	
5'	62.33, 62.35, CH <sub>2</sub> <sup>d</sup>	3.83-3.90, m	4'	3', 4' 2'	

<sup>a</sup>Performed in CDCl<sub>3</sub>, ppm, type established by phase-sensitive HSQC. <sup>b</sup>125 MHz. <sup>c</sup>500 MHz. <sup>d</sup>These signals are represented as 2xs, presumably because of the two diastereotopic carbons (C8 and C1'). <sup>e</sup>Some  $J$  values were calculated from DQF-COSY (Double Quantum Filtered COSY) experiment.

**Table S4:** Summary of yields and conditions for the oxidation of **2** to yield **3**.

Trial Number	Scale	Purification Conditions	Yield
1	4.01 g, 13.1 mmol	EtOAc:Hexane (5:95 to 20:80) Column length: 2.1 x 15 cm Silica gel	1.4 g, 33%
2	5.11 g, 16.6 mmol		1.7 g, 32%
3	4.01 g, 13.1 mmol		1.38 g, 33%
4	3.1 g, 10 mmol		1.2 g, 37%

**Table S5:** Summary of yields and conditions for the bromination and subsequent diphosphorylation of **6** to yield **1**.

Batch No.	Starting Material (Alcohol, <b>6</b> )	Cellulose Column Packing Length (cm)	Eluent	Flow Rate	Yield
1	100 mg, 0.36 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	4.0-4.5 mL/min	39 mg 25%
2	100 mg, 0.36 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	4.0-5.0 mL/min	42 mg 27%
3	80 mg, 0.31 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	5.0-6.0 mL/min	29 mg 21%
4	100 mg, 0.36 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	5.0-6.0 mL/min	44 mg 28%
5	200 mg, 0.72 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	5.0-6.0 mL/min	66 mg 21%
6	100 mg, 0.36 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	5.0-6.0 mL/min	42 mg 27%
7	100 mg, 0.36 mmol	2.5 x 21	THF:0.1 M NH <sub>4</sub> HCO <sub>3</sub> (90:10) 200 mL, then (80:20) 200 mL	5.0-6.0 mL/min	43 mg 28%


**Table S6:** Lists of prenylated proteins enriched from ESCs, ES-MNs and ES-As.

*Included as a separate Excel File (Table S6).*


**Table S7:** Results from gprofiler enrichment analysis of prenylated proteins ESCs, ES-As and ES-MNs.  
*Included as a separate Excel File (Table S7).*

## References

Ikiz B, Alvarez MJ, Ré DB, Le Verche V, Politi K, Lotti F, Phani S, Pradhan R, Yu C, Croft GF, Jacquier A, Henderson CE, Califano A, Przedborski S. The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. *Cell Rep.* 2015 Jul 14;12(2):335-45. doi: 10.1016/j.celrep.2015.06.019. Epub 2015 Jul 2. PMID: 26146077; PMCID: PMC4646662.




Compound 2 <sup>1</sup>H NMR




Compound **3** <sup>1</sup>H NMR







Compound 5 <sup>1</sup>H NMR





Compound 6 <sup>1</sup>H NMR



Compound 1 <sup>1</sup>H NMR





Compound **1** <sup>13</sup>C NMR